MarketPulse

drug approval

5 articles
The Motley FoolThe Motley Fool··Adria Cimino

Vertex Pharma's $600 Target Hinges on Diversification Beyond Cystic Fibrosis

Vertex Pharmaceuticals eyes 25% stock upside to $600 as it expands beyond cystic fibrosis with new drug approvals and kidney disease candidate povetacicept.
VRTXbiotechrevenue growth
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling $PRAX Soars 685% as $80.5M Investment Bets on Dual FDA Filings

$PRAX surges 685% annually, securing $80.5M from Driehaus Capital. Two FDA applications pending for neurological therapies with potential $20B+ revenue.
TSMPRAXGHbiotechinstitutional investment
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Oral GLP-1 Drug Could Reshape Weight Loss Market as Novo Nordisk Faces Competition

Eli Lilly's orforglipron oral GLP-1 drug offers no food restrictions and dual obesity-diabetes approval potential, threatening Novo Nordisk's oral Wegovy dominance.
LLYNVOpharmaceutical competitionweight-loss drug
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

CORT Plunges 50% After FDA Rejection; Securities Fraud Lawsuit Filed

Corcept Therapeutics faces class action lawsuit after FDA rejected relacorilant drug application, triggering 50% stock collapse and disclosure allegations.
CORTsecurities fraudclass action lawsuit
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Pharmaceuticals: Evaluating Path to Million-Dollar Returns

Vertex Pharmaceuticals needs 26% annual growth to turn $100K into $1M by 2036, but its maturing cystic fibrosis franchise and competitive pressures make this ambitious target unlikely despite solid fundamentals.
LLYVRTXbiotechcystic fibrosis